Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hydrolethalus syndrome protein 1 (HYLS1) is a highly conserved protein localized to centrioles and basal bodies, where it is essential for the formation and proper function of cilia (ciliogenesis)[1][2][3][4]. HYLS1 mediates centriole elongation and recruits key components required for building the ciliary transition fibers and transition zone, thereby regulating the selective gating of proteins into and out of the cilium[1][3][4]. Disruption or mutation of HYLS1 results in severe developmental defects, including hydrolethalus syndrome—a lethal ciliopathy presenting with profound abnormalities in fetal development, particularly brain malformations[1][2][4]. In mammals, HYLS1 has further roles in modulating ciliary signaling, notably the Hedgehog pathway, through interactions with other ciliary proteins such as PIPKIγ and FBF1[2][4]. Although it is a fundamental component required for healthy cell and organismal development, HYLS1 itself is not a direct therapeutic target, and there are no drugs known to interact with it in a clinical context[2][4].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hydrolethalus syndrome protein 1 (HYLS1).